lonafarnib

may enhance the serum concentration of CYP3A4 inhibitors

curcumin

may enhance the serum concentration of CYP3A4 inhibitors

glecaprevir

may enhance the serum concentration of CYP3A4 inhibitors

caspofungin

may enhance the serum concentration of CYP3A4 inhibitors

may enhance the serum concentration of CYP3A4 inhibitors

grapefruit

It may enhance the effect when combined with grapefruit by CYP3A4 metabolism

maralixibat

may enhance the concentration of serum when combined with lonafarnib

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

mibefradil

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

citalopram

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

efavirenz

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

nafcillin

When naficillin combines with lonafarnib, nafcillin will decrease the effect of action of lonafarnib by affecting enzyme CYP3A4 metabolism.

ivosidenib

when both drugs are combined, there may be a decreased effect of lonafarnib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  

lapatinib

lapatinib increases the effect of lonafarnib by altering the intestinal or hepatic CYP3A4 enzyme metabolism

bicalutamide

when both drugs are combined, there may be an increased effect of Lonafarnib by affecting hepatic or intestinal enzyme CYP3A4 metabolism 

pexidartinib

pexidartinib decreases the effect or level of lonafarnib by altering the intestinal/hepatic CYP3A4 enzyme metabolism

osilodrostat

may enhance the serum concentration of CYP3A4 inhibitors

amlodipine/telmisartan

may enhance the serum concentration of CYP3A4 inhibitors

may enhance the serum concentration of CYP3A4 inhibitors

abametapir

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

amiodarone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

amobarbital

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

apalutamide

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

butabarbital

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

butalbital

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

carbamazepine

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

ceritinib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

doxycycline

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

dronedarone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

efavirenz

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

elagolix

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

itraconazole

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

ivacaftor

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

voxelotor

may enhance the serum concentration of CYP3A4 Inhibitors

ifosfamide

when both drugs combine lonafarnib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.

cyclophosphamide

cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.

alpelisib

when both drugs are combined, there may be a decreased level of serum concentration of lonafarnib   

brentuximab

the lonafarnib, interacting with brentuximab, shows increased effect by altering the intestinal or hepatic CYP3A4 enzyme metabolism.

lenvatinib

the effect of lonafarnib is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism. Avoid or take an alternate drug.

enzalutamide

CYP3A strong enhancers of the small intestine may reduce the bioavailability of lonafarnib

regorafenib

it will increase the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism

ribociclib

it increases the concentration of lonafarnib in serum

ruxolitinib

it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism

methimazole

methimazole increases the effect of lonafarnib by altering intestinal or hepatic metabolism

danazol

danazol increases the effect or level of lonafarnib by altering intestinal or hepatic CYP3A4 enzyme metabolism

zonisamide

may increase the level of zonisamide by affecting hepatic enzyme CYP3A4 metabolism

elagolix

OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum

OATP1B1/1B3 inhibitors increase the concentration of elbasvir and grazoprevir in the serum

voxilaprevir

OATP1B1/1B3 inhibitors increase the concentration of voxilaprevir in the serum

may enhance the serum concentration of elbasvir/grazoprevir

abemaciclib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

acalabrutinib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

acetaminophen

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

buspirone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

busulfan

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

cabozantinib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

calcifediol

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

drospirenone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

elacestrant

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

ergotamine

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

losartan

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

lurasidone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

mefloquine

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

asunaprevir

OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum

OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of elbasvir and grazoprevir in the serum

revefenacin

BCRP/ABCG2 inhibitors increase the concentration of pazobanib in the serum

taurursodiol

OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of taurursodiol in the serum

leniolisib

it increases the concentration of OATP1B1/1B3 substrates in the serum

zuclopenthixol

it may diminish the metabolism when combined with zuclopenthixol

epcoritamab

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

adagrasib

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

imiquimod topical

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

fluorouracil topical

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

peginterferon alfa-2b

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

dexrabeprazole

When dexrabeprazole and lonafarnib is used together, this leads to reduction in the dexrabeprazole’s metabolism

carbimazole

It may enhance the risk of adverse effects when combined with Metabolic agents

potassium perchlorate

It may enhance the risk of adverse effects when combined with Metabolic agents

simvastatin

lonafarnib: it may enhance the serum concentration of simvastatin

topotecan

when both drugs are combined, there may be a reduced excretion rate of topotecan and result in an elevated level of serum concentration  

daunorubicin

increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter

idarubicin

increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter

voclosporin

may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates

brincidofovir

OATP1B1/1B3 inhibitors increase the concentration of brincidofovir in the serum

eluxadoline

OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum

pretomanid

may increase the serum concentration of OAT1/3 substrates

atogepant

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

duvelisib

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

edoxaban

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

eletriptan

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

tacrolimus

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

talazoparib

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

valrubicin

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

epirubicin

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

mitoxantrone

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

mitomycin

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

paclitaxel/encequidar

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

paclitaxel

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

cabazitaxel

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

docetaxel

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

sacituzumab govitecan

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

topotecan

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

etoposide

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

irinotecan

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

teniposide

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

Dosage Forms & Strengths

Capsule

50mg

75mg

Indicated for Hutchinson-Gilford Progeria Syndrome
Initial dose: 115 mg/ m2 orally two times a day in the morning, evening with meals
After four months: enhance the dose to 150 mg/ m2 orally two times a day
Adjust the total daily dose to the nearest 25 mg increments
Progeroid Laminopathies
Initial dose: 115 mg/ m2 orally two times a day in the morning, evening with meals
After four months: enhance the dose to 150 mg/ m2 orally two times a day
Adjust the total daily dose to the nearest 25 mg increments
Note:
This drug is generally indicated for the treatment of processing-deficient progeroid laminopathies typically characterized by the accumulation of progerin-like protein due to heterozygous LMNA mutation, as well as for homozygous/compound heterozygous ZMPSTE24 mutations

Dosage Forms & Strengths

Capsule

50mg

75mg

Indicated for Hutchinson-Gilford Progeria Syndrome
Age >12 months, BSA >0.39 m2
Initial dose: 115 mg/ m2 orally two times a day in the morning, evening with meals
After four months: enhance the dose to 150 mg/ m2 orally two times a day
Adjust the total daily dose to the nearest 25 mg increments
Progeroid Laminopathies
Age >12 months, BSA >0.39 m2
Initial dose: 115 mg/ m2 orally two times a day in the morning, evening with meals
After four months: enhance the dose to 150 mg/ m2 orally two times a day
Adjust the total daily dose to the nearest 25 mg increments
Note:
This drug is generally indicated for the treatment of processing-deficient progeroid laminopathies typically characterized by the accumulation of progerin-like protein due to heterozygous LMNA mutation, as well as for homozygous/compound heterozygous ZMPSTE24 mutations

Refer to adult dosing

Frequency defined

>10%

Infection (78%)

Abdominal pain (48%)

Electrolyte abnormalities (43%)

Nausea (56%)

Headache (37%)

Musculoskeletal pain (48%)

Constipation (22%)

Decreased weight (37%)

Myelosuppression (35%)

Increased ALT (27%)

Diarrhea (81%)

Increased AST (35%)

Cerebral ischemia (11%)

Decreased appetite/anorexia (53%)

Ocular changes (24%)

Pyrexia (14%)

Hypertension (29%)

Rash (11%)

Rhinitis (19%)

Epistaxis (21%)

Fatigue (51%)

Upper respiratory tract infection (51%)

Cough (33%)

Vomiting (90%)

Decreased blood bicarbonate (33%)

1-10%

Dehydration (5%)

Flatulence (6%)

Pruritus (8%)

Mucositis (8%)

Depressed mood (5%)

Black Box Warning:

lonafarnib has a black box warning for the potential risk of severe or fatal liver toxicity. This warning is based on reports of liver toxicity in clinical trials, including hepatic failure and death.

Patients taking lonafarnib should have regular liver function tests to monitor for any signs of liver damage, such as elevated liver enzymes. The drug should be discontinued if liver function test abnormalities persist or worsen or there are clinical signs of liver damage.

lonafarnib should not be used in patients with moderate or severe hepatic impairment, and caution should be exercised in patients with mild hepatic impairment. The drug should also be used cautiously in patients taking other medications that cause liver damage.

Contraindication/Caution:

Contraindication

lonafarnib has several contraindications, which means the drug should not be used on specific individuals. These include:

Hypersensitivity: lonafarnib is contraindicated in individuals with known hypersensitivity/allergy to the drug or its components.
Pregnancy and breastfeeding: lonafarnib may cause harm to a developing fetus and should not be generally used during pregnancy. It is also unknown whether the drug is excreted into the breast milk, so it should not be used while breastfeeding.
Severe hepatic impairment: lonafarnib is contraindicated in individuals with severe hepatic impairment, as it may exacerbate liver damage and enhance the risk of liver toxicity.
Use with certain medications: lonafarnib may interact with certain medications, such as potent CYP3A inhibitors and inducers, and should not be combined.
Children: The safety and effectiveness of lonafarnib have yet to be established in children under 18 years of age; it is generally not recommended for use in this population.

It is essential to discuss all current medications and medical conditions with a healthcare provider before taking lonafarnib to determine whether it is appropriate and safe for use.

Caution

Several cautions should be considered before taking lonafarnib. These include:

Hepatic impairment: lonafarnib should be used cautiously in individuals with mild hepatic impairment, as the drug may increase the risk of liver toxicity.
Renal impairment: The safety and effectiveness of lonafarnib have not been established in individuals with renal impairment, and caution should be exercised in this population.
Bleeding disorders: lonafarnib may cause a decrease in blood cell counts, which can enhance the risk of bleeding. Caution should be exercised in individuals with bleeding disorders, and blood counts should be monitored regularly.
Infections: lonafarnib may also increase the risk of infection due to decreased blood cell counts. Caution should be exercised in individuals with a history of infections, and signs of infection should be monitored closely.
Interactions with other medications: lonafarnib may interact with other medications, including CYP3A inhibitors and inducers, and caution should be maintained when using these drugs in combination.
QT prolongation: lonafarnib may cause QT prolongation, increasing the risk of potentially life-threatening cardiac arrhythmias. Caution should be exercised in individuals with a history of QT prolongation or other cardiac conditions.
Elderly: The safety and effectiveness of lonafarnib in elderly individuals have not been established, and caution should be exercised in this population.

As with all drugs, it is essential to discuss any current medications and medical conditions with a healthcare provider before taking lonafarnib to determine if the drug is appropriate and safe for use.

Pregnancy consideration:

US FDA pregnancy category: Not assigned

Lactation:  

Excreted into human milk is Not known.

Pregnancy category:

Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.       
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women       
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.      
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.       
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.       
Category N: There is no data available for the drug under this category

Pharmacology:

lonafarnib is a medication that belongs to a class of drugs known as farnesyltransferase inhibitors. Farnesyltransferase is an enzyme involved in modifying certain proteins in cells, including the protein called lamin A. Mutations in the gene that encodes lamin A can cause several rare genetic disorders, including progeria and progeroid laminopathies.

lonafarnib works by inhibiting the activity of farnesyltransferase, which can prevent the abnormal modification of lamin A in cells. This can improve cellular function and slow disease progression in individuals with these rare genetic disorders.

lonafarnib is also being studied as a potential treatment for acute myeloid leukemia (AML), a cancer affecting the blood and bone marrow. The drug acts by targeting a protein called RAS, which is often mutated in AML and can contribute to the growth, spread of cancer cells.

Pharmacodynamics:

Mechanism of action: The method by which it works is through an FTI taken orally. The inhibitor targets Farnesyltransferase, an enzyme that modifies proteins through prenylation.

A mutation in the LMNA gene results in the excessive production of progerin, an aberrantly farnesylated protein. The build-up of progerin in the inner nuclear membrane is caused by persistent farnesylation and is at least partly responsible for Hutchinson-Gilford Progeria Syndrome (HGPS).

The accumulation of faulty lamin A protein renders the nucleus unstable, resulting in premature aging in children with progeria.

Pharmacokinetics:

Absorption

lonafarnib is well absorbed after oral administration, with peak plasma concentrations occurring approximately 2-4 hours after dosing. The drug is administered orally as capsules and should be generally taken with food, as this improves its absorption.

Distribution

lonafarnib is extensively distributed throughout the body, with a volume of distribution of approximately 0.5-1.5 L/kg. The drug is highly protein-bound, approximately 99% bound to plasma proteins.

Metabolism

The liver primarily metabolizes lonafarnib through oxidative metabolism, mediated by the cytochrome P450 (CYP) enzyme system. The primary metabolite of lonafarnib is called lonafarnib M, which is pharmacologically active and contributes to the drug’s effects.

Elimination and Excretion

lonafarnib and its metabolites are primarily eliminated in the feces, with only a tiny amount in the urine. The elimination half-life of lonafarnib is approximately 3-5 hours.

Administration:

Oral administration

lonafarnib is available as a capsule for oral administration. The capsules should be generally swallowed whole and not crushed or chewed.

The recommended dose of lonafarnib varies depending on the indication and the patient’s medical history. The drug should be taken under the close monitoring of a physician who is experienced in the use of the drug.

lonafarnib should be taken with food, as this may help to improve absorption and reduce the risk of gastrointestinal (GI) side effects such as nausea and vomiting. The drug should be taken simultaneously each day to maintain consistent blood levels.

If a dose is missed, taking it as soon as possible is generally recommended. However, if the next scheduled dose is missed, it should be skipped and the following dose should be taken at the appropriate time. It is important to avoid taking a double dose of the medication to compensate for the missed dose.

If a patient experiences any side effects while taking lonafarnib, they should contact their healthcare provider for advice. If a patient experiences a severe or life-threatening side effect, they should seek emergency medical attention immediately.

It is key to follow all instructions provided by the healthcare provider regarding the administration of lonafarnib and to not adjust the dose or frequency of the drug without first consulting with the provider.

Patient information leaflet

Generic Name: lonafarnib 

Pronounced: [ LOE-na-FAR-nib ]

Why do we use lonafarnib?

lonafarnib is a medication that is used for the treatment of several rare genetic disorders. These disorders are caused by gene mutations that regulate the function of a farnesyltransferase protein. lonafarnib works by inhibiting the activity of farnesyltransferase, which can improve symptoms and slow disease progression in affected individuals.

The specific uses of lonafarnib include:

Progeria: lonafarnib is approved for treating Hutchinson-Gilford Progeria Syndrome (HGPS), also known as progeria. This rare genetic disorder causes premature aging in children and is typically caused by a mutation in the LMNA gene. lonafarnib can improve weight gain, bone density, and cardiovascular function in individuals with HGPS.
Progeroid laminopathies: lonafarnib is also used to treat other progeroid laminopathies, which are rare genetic disorders similar to HGPS but have different genetic causes. These disorders include Mandibuloacral Dysplasia Type A (MADA), Mandibuloacral Dysplasia Type B (MADB), and Restrictive Dermopathy (RD).
Acute myeloid leukemia (AML): lonafarnib is currently being studied as a potential treatment for AML, a cancer affecting the blood and bone marrow. The drug acts by targeting a protein called RAS, which is often mutated in AML and can contribute to the growth, spread of cancer cells.

It is important to note that lonafarnib is only approved for use in specific indications and should only be used under the close monitor of a physician who is experienced in drug use.

LEARNING & CME

View All

Latest Posts

Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment

November 15, 2025

New Prediction Model Guides CKD Patients on Dialysis vs. Conservative Care

November 14, 2025

World’s TB Fight Faces Setback Amid Funding Gaps

November 13, 2025

A Common Infection Turns Dangerous: EBV’s Hidden Role in Lupus

November 13, 2025

lonafarnib 

Brand Name :

Zokinvy

Synonyms :

lonafarnib 

Class :

Farnesyltransferase Inhibitors, Miscellaneous metabolic agents

Dosage Forms & Strengths

Capsule

50mg

75mg

Dosage Forms & Strengths

Capsule

50mg

75mg

Refer to adult dosing

DRUG INTERACTION

lonafarnib

&

Pembrolizumab / Berahyaluronidase
Bumetanide Intranasal
Gemcitabine intravesical
Rilzabrutinib
Zopapogene
Aceclidine
aluminium hydroxide
benzralizumab (Rx)
Rituximab
Trimetrexate Glucuronate
Mirdametinib
Suzetrigine
Potassium acid phosphate
Acellular Tissue Engineered Vessel
crinecerfont (pending approval from FDA)
Revumenib
pembrolizumab (Rx)
azathioprine (Rx)
Gemcitabine (Rx)
Seladelpar
Atezolizumab / Hyaluronidase-tqjs
Axatilimab-csfr
Afamitresgene Autoleucel
Lazertinib
Ocrelizumab / Hyaluronidase ocsq
Lebrikizumab
naloxone intranasal
clomiphene
patisiran
imetelstat
phenylephrine ophthalmic
myoinositol
vasicinone
soda lime
fisetin
Reynoutria Japonica
Coco Monoethanolamide
Betadex
lithopone
cyperus rotundus
papaya juice
1-naphthaleneacetic acid
Nordazepam
Glechoma hederacea
Alternanthera sessilis
nicofetamide
napthol asol
cocamidopropyl betaine
musa x paradisiaca
dicyclomine/mefenamic acid
Sorghum
Manganese citrate
tovorafenib
mefenamic acid/paracetamol
eschscholzia californica
canna indica root
tranexamic acid/mefenamic acid
dexverapamil
sitogluside
secalciferol
cefatrizine
Sedum Acre
Flurogestone
Fluocortin
Bifendate
piprozolin
aminacrine undecylate
ethylenediamine mandelate
pelubiprofen
hesperetin
butethamine
epitiostanol
androstenediol
Nitroxoline
Iocarmic acid
Capobenic acid
dordaviprone (investigational drug)
Vitexin
Friluglanstat (investigational drug)
scorias spongiosa
Luseogliflozin
indoxacarb
prademagene zamikeracel
fidanacogene elaparvovec-dzkt
albifylline
idanpramine
araneus diadematus
Sulfamazone
Lycosa tarantula
malotilate
Ethacizine
Namilumab
Latrunculin B
stachyose
platinic oxide
iopronic acid
calcium chloride / potassium chloride/lactic acid/ sodium chloride/sodium hydroxide/sodium lactate solution
citric acid/ sodium bicarbonate/ sodium carbonate anhydrous
vadadustat
permethrin medical grade cis/trans isomers 25/75
lutetium, isotope of mass 177
human normal immunoglobulin
sacrosidase
apadamtase alfa, recombinant
acetyl hexapeptide-8 amide
pemivibart (Investigational)
govorestat
Zanidatamab
sotatеrcеpt
MV 140 vaccine
leuprorelin implant
cinchocaine hydrochloride/fluocortolone hexanoate/fluocortolone pivalate
Beautyberry
risedronate/calcium/vitamin D3
rhubarb extract/senna leaf/sulphur purified/wood charcoal
boric acid/kaolin/methyl salicylate/peppermint oil/thymol
docosahexaenoic acid/eicospentaenoic acid
aluminium hydroxide/magnesium hydroxide/simethicone
gentamicin/hydrocortisone
succinylcholine
sinefungin
letibotulinumtoxinA
coal tar/coconut oil/salicylic acid
camphor/camphor oil white/capsicum oleoresin /menthol/methyl salicylate
thioglycolic acid
acetic acid auricular
roluperidone
hydrocortisone/crotamiton topical
nystatin/chlorhexidine
aluminium chloride hexahydrate
ketoprofen topical
Chlormethine
podophyllotoxin
urea/lactic acid
autologous chondrocytes implant
afelimomab
gepotidacin
fludroxycortide
fentanyl transdermal
erythromycin/zinc acetate
dibotermin alfa powder
desferrioxamine mesilate
choline salicylate/magnesium salicylate
castor oil/peru balsam/trypsin
betamethasone/dexchlorpheniramine maleate
benzalkonium chloride solution/cetrimide
barzolvolimab
ascorbic acid / calcium laevulinate / nicotinamide / calcium pantothenate / calcium chloride / riboflavine / pyridoxine hydrochloride / thiamine hydrochloride
argipressin
arachis oil refined/chlorobutanol hemihydrate
arachis oil/eucalyptol/nutmeg oil/terpineol
ammonium chloride/diphenhydramine hydrochloride/levomenthol
amino acid mixture d / calcium chloride dihydrate / glucose monohydrate / glycine / magnesium chloride hexahydrate / olive oil / potassium chloride / sodium acetate trihydrate / sodium glycerophosphate pentahydrate / soya-bean oil
biotin/colecalciferol/copper (ii)sulfate dried/ cyanocobalamine/ dl-alpha tocopherol acetate/dibasic calcium phosphate anhydrous/folic acid/iron (ii)sulfate dried/ lecithin/ magnesium sulfate dried/ nicotinamide/ pyridoxine hydrochloride/ riboflavin
ampicillin sodium / cloxacillin sodium
undecylenic acid, undecylenate salts, zincundecate
omeprazole/sodium bicarbonate
efgartigimod alfa/hyaluronidase
xylometazoline/ipratropium
cefepime and enmetazobactam
isotonic sodium chloride
bee venom allergen injection
fentanyl intranasal
alglucosidase alfa
triprolidine/pseudoephedrine
pegademase bovine
castor oil and peru balsam
camphor/eucalyptus oil/menthol
oxyquinoline/sodium lauryl sulfate
somatorelin
menotrophin injection
menadiol
hylan g-f 20
cefepime and taniborbactum
water avens
camphor/menthol
acoramidis
elafibranor
arrowroot
miconazole nitrate/hydrocortisone
vildagliptin/metformin
dobesilic acid
aroxybutynin and atomoxetine
hygromycin
linvoseltamab
nemolizumab
aceprometazine
limaprost
oxazolam
trimegestone
teceleukin
beauty berry
dinotefuran
imiprothrin
transfluthrin
thymalfasin
technetium Tc 99m tilmanocept
glepaglutide
marstacimab
pixantrone
Andiroba
arabinoxylan
arenaria rubra
etripamil
jequirity
jiaogulan
dusquetide
rolipram
tradipitant
sinfungin
diclofenac/omeprazole
brinzolamide and timolol maleate
wormseed
wormwood
wood sorrel
carmellose sodium
ibandronic acid
cinnarizine and dimenhydrinate
ursodeoxycholic acid
rhubarb extract/salicylic acid
butamirate citrate
fumitory
taheebo
uva ursi
vervain
coleus
coltsfoot
crampbark
plantain
potassium nitrate and silver nitrate
gelsemium
gentian
glucomannan
walnut
meadowsweet
midomafetamine
pennyroyal
periwinkle
betony
bitter orange
bladderwrack
bloodroot
emu oil
garcinia
yellow dock
burdock
dehydroepiandrosterone
aucubin
jasmone
resacetophenone
ecamsule ditriethanolamine
feclobuzone
fenoprop triethanolamine
verdyl acetate
caffeic acid
cyclamen aldehyde
dicetyldimonium chloride
wogonin
impacarzine
laurylpyridinium chloride
stepronin
matrine
sakuranin
cannabichromene
sandalore
sabinene
oxypaeoniflora
ethylhexyl pelargonate
acrylonitrile
allyl alcohol
dipalmitoylethyl hydroxyethylmonium methosulfate
butidrine
clothiapine
propanediol dicaprylate
buchu
undecanol
enilconazole
xymenynic acid
angelica
nizubaglustat
resomelagon
ulecaciclib
apple cider vinegar
bacopa
barley grass
dandelion
deer velvet
dolomite
bugleweed
bupleurum
glyceryltrinitrate
pociredir
asnuciclib
actalycabtagene autoleucel
butantan–dengue vaccine
travoprost/timolol
furosemide/potassium chloride
amylamine
jaborandi
patritumab deruxtecan
jackfruit
sterculia
ascorbigen
ashitaba
androstenetrione
andrachne
cosibelimab
racecadotril
neomycin/chlorhexidine
octocog alfa
cetrimide
ispaghula husk
polyhexanide
octenidine
polygeline
heparinoid
jewelweed
boldo
anizatrectinib
alpinia
henbane
cynanchum vincetoxicum root and sulfur
boditrectinib
izumerogant
zavondemstat
abuta
fadogia agrestis
fly agaric mushroom
meptazinol
methoxyflurane
tramadol/dexketoprofen
betaine/polyhexanide
filgotinib
inosine acedoben dimepranol
alverine citrate
hyoscine butylbromide
senna+ ispaghula
cabbage palm
cajeput oil
calanus oil
calamint
canada balsam
carnosine
alverine citrate/simeticone
dihydroartemisinin/piperaquine
mebeverine/ispaghula
calcipotriol
tacalcitol
triethyl citrate/ethyl linoleate
sodium dilauramidoglutamide lysine
fazamorexant
avibactam tomilopil and ceftibuten
drostanolone
tigilanol tiglate
isorhynchophylline
rhynchophylline
crisugabalin
epigallocatechin gallate
clomocycline
corynoxeine
isocorynoxeine
Culmerciclib
Neladenoson
ambrein
hexylcaine
phensuximide
resencatinib (investigational)
rolusafine
pumecitinib
arhalofenic acid
berdazimer sodium
benzquinamide
clidinium
sulfametopyrazine
fulzerasib (Investigational Drug)
rovadicitinib (Investigational Drug)
Upleganan (Investigational Drug)
menthyl ethylamido oxalate
quaternium-90 montmorillonite
unecritinib (investigational drug)
etohexadiol
guaiol
proximadiol
verdinexor
sofnobrutinib
talbutal
ethoxzolamide
propiomazine
enprofylline
phenmetrazine
merigolix
pralurbactam
neracorvir
vonifimod
apaziquone hydroquinone
darizmetinib
zandelisib
xininurad
ritivixibat
amiselimod phosphate (investigational drug)
emzeltrectinib (investigational drug)
ficonalkib
cinalukast
ulobetasol
candoxatril
nitrofural
acetyldigitoxin
bentiromide
dextrothyroxine
chlorotrianisene
remikiren
pipobroman
vidarabine
immune globulin intravenous, human-stwk
spermine
serine
N-acetyl glucosamine
valine
adenine
asparagine
citrulline
adinazolam
interferon alfacon-1
interferon alfa-n1
felypressin
birch triterpenes
pyridoxal phosphate
technetium Tc-99m arcitumomab
beta-alanine
dihomo-gamma-linolenic acid
urea/hydrocortisone
R21/Matrix-M vaccine
povidone-iodine (ophthalmic)
pheniramine
hydrocortisone rectal
chloroxylenol/pramoxine/zinc acetate
chloroxylenol/pramoxine
dextrose/sucrose/vitamin C/zinc sulphate
furazolidone/metronidazole/dicyclomine
ergocalciferol (vitamin D2)
benoxaprofen (discontinued)
teicoplanin
carbomer
chromic chloride / iron (ii) chloride tetrahydrate / potassium iodide / manganese chloride / sodium fluoride / sodium selenite pentahydrate / sodium molybdate dihydrate / zinc chloride/ cupric chloride
bufylline
lidocaine/prilocaine
opium tincture, squill oxymel
dibrompropamidine
metronidazole/tetracycline/bismuth subsalicylate
agnus- castus
velaglucerase alfa
alendronic acid / colecalciferol
bimatoprost / timolol
efbemalenograstim alfa
dried ferrous sulfate/folic acid
dried ferrous sulfate / sodium ascorbate
nirogacestat
soya-bean oil, medium-chain triglycerides
demeclocycline hydrochloride and triamcinolone acetonide
fusidic acid / hydrocortisone acetate
macrogol
storax, benzoin
nomegestrol acetate/estradiol
flumetasone pivalate/ clioquinol
berdazimer topical (Pending FDA Approval)
buflomedil
butobarbital
andexanet alfa
methoxypolyethylene glycol-epoetin beta
viscum abietis
pramoxine vaginal
bupivacaine implant
cromolyn sodium, inhaled
pneumococcal vaccine 20-valent
bimatoprost ophthalmic implant
tick-borne encephalitis vaccine
chloroprocaine ophthalmic
travoprost intraocular implant (Pending FDA approval)
typhoid polysaccharide vaccine
sodium phosphate
human papillomavirus vaccine, nonavalent
peanut immunotherapy epicutaneous (FDA approval pending)
cromolyn sodium, intranasal
red blood cells(Blood component)
oral mucoadhesive
clindamycin vaginal
whole blood (Blood Component)
fibrinogen/thrombin
levothyroxine/liothyronine
ipratropium intranasal
metronidazole vaginal
cyamemazine
brinase
reviparin
ulinastatin
saruplase
acepromazine
emylcamate
methionine
amino acids and electrolytes in dextrose with calcium
slippery elm
camostat
hemoglobin crosfumaril
moperone
chlormidazole
brilaroxazine
palopegteriparatide
diazepam buccal
benegrastim (pending for FDA approval)
COVID-19 vaccine, adjuvanted-Novavax
vestronidase alfa-vjbk
tebipenem (Pending FDA Approval)
tislelizumab (Pending FDA Approval)
zolbetuximab (Pending FDA Approval)
zoliflodacin (pending FDA approval)
zibotentan and dapagliflozin
fluorine F18 DCFPyL
debamestrocel
givinostat
amubarvimab and romlusevimab(Pending FDA Approval)
sabizabulin(Pending FDA approval)
fexapotide(Phase 3 Clinical trial)
diatrizoic acid
drotaverine
diethyl phthalate
enclomiphene
epalrestat
ethamsylate
flupirtine
imidurea
sodium glycolate
feracrylum
ethacridine
furazolidone/metronidazole
ozagrel hydrochloride
leptazol
l-glutamic acid /vitamin B complex
etizolam
etizolam/propranolol
ethoheptazine citrate
etophylline and theophylline
etophylline
finger millet
drotaverine/mefenamic acid
dichloroxylenol
pneumococcal 7-valent vaccine
diclofenac and metaxalone
dipivefrin ophthalmic
enbucrilate
potassium citrate and citric acid
potassium gluconate
aclarubicin
alfuzosin/dutasteride
adrenochrome monosemicarbazone
selenium sulfide topical
sertaconazole
amorolfine cream
amsacrine
amylmetacresol
sulfonated phenolics in aqueous solution
technetium Tc-99m sulfur colloid
raltitrexed
romiplostim
acediasulfone
azulene
acebrophylline
clonazepam/escitalopram oxalate
allylestrenol
andrographolide
artemotil
technetium Tc-99m sestamibi
rubidium Rb-82
somapacitan
sodium sulfate, magnesium sulfate and potassium sulfate
almitrine
gramicidin
nikethamide
technetium Tc-99m sodium pertechnetate
betiatide
prilocaine/epinephrine
amlexanox
acetaminophen/salicylamide/phenyltoloxamine
neomycin topical
zilucoplan
antazoline and xylometazoline
toripalimab
iron isomaltoside
meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine
meningococcal A C Y and W-135 diphtheria conjugate vaccine
tetradecyl Sulfuric Acid
benzoyl peroxide, clindamycin phosphate, adapalene
ethylephedrine
actarit
pyrantel tartrate
tenofovir disoproxil fumarate or tenofovir DF
melitracen
amitriptylinoxide(Phase 4 Clinical Trials)
threonine
ditiocarb zinc
epicriptine
levallorphan
kinetin
laurocapram
pentagastrin
parthenolide
nicoboxil
protionamide
prulifloxacin
proscillaridin
tizanidine and rofecoxib
tolnaftate, gentamicin, chinoform and betamethasone valerate
pine bark extract
pipenzolate methylbromide
bephenium hydroxynaphthoate
niclosamide
pyrvinium
pipenzolate methylbromide/phenobarbitone
piracetam/ginkgo biloba/vinpocetine
benzyl benzoate/disulfiram
benzyl benzoate
loperamide/simethicone
piroctone olamine
sodium fusidate
piroxicam topical/capsaicin/menthol/methyl salicylate
sodium metabisulfite
sodium lauryl sulfate
taspoglutide
glyclopyramide
tolnaftate, gentamicin, iodochlorohydroxyquinoline, chlorocresol, betamethasone valerate
serratiopeptidase
sodium antimony gluconate
triamterene / benzthiazide
tribenoside / lidocaine
triclocarban
triprolidine/dextromethorphan
vitamins/minerals/omega-3 Fatty acids
soyabean oil
sucralfate/oxethazaine
sucralfate/tinidazole/povidone iodine
sodium cromoglycate
aloe vera/liquid paraffin/white soft paraffin
aloe vera/jojoba oil/vitamin E
allantoin/triclosan/vitamin e/zinc oxide
alpha-Lipoic acid/minerals/multivitamins
alprazolam/paracetamol
alprazolam/melatonin
azithromycin/ambroxol
atorvastatin/clopidogrel/aspirin
aceclofenac, paracetamol and serratiopeptidase
alfacalcidol, vitamin B-complex, minerals and antioxidants
alpha- lipoic acid, vitamin b complex and vitamin c
alpha-galactosidase and simethicone
alpha-galactosidase, amylase, proteases, lipase and lactase
amikacin and cefepime
aminophylline, ephedrine and phenobarbitone
artesunate, sulphadoxine and pyrimethamine
finasteride/tamsulosin
flavoxate/ofloxacin
fenofibrate/metformin
lignocaine, hydrocortisone topical and allantoin
linoleic acid and sodium lactate
troxerutin
meclizine/nicotinic acid
mecobalamin/ginkgo Biloba
spirulina
loperamide and furazolidone
ketoconazole/cetrimide
ketoconazole/zinc pyrithione
lercanidipine/atenolol
levocetirizine/montelukast/ambroxol
levarterenol
levocetirizine/phenylpropanolamine
indapamide/amlodipine
itopride/methyl polysiloxane
mebendazole/levamisole
eberconazole/mometasone
gliclazide/metformin/pioglitazone
fluconazole/tinidazole
haemocoagulase
halometasone
hesperidin
imipramine/chlordiazepoxide
idebenone / l-arginine / zinc sulphate/selenium/proanthocyanidin
mecobalamin and piracetam
mesterolone
mosapride and pantoprazole
atorvastatin, co enzyme q10, vitamin e, zinc, and selenium
azithromycin and benzalkonium chloride
beta carotene, vitamin c, vitamin e, minerals, lutein, eicosapentaenoic acid, docosahexenoic acid and vit b12
alpha-galactosidase
aloe vera gel/vitamin e/lactic acid
aloe vera gel/jojoba/vitamin e/glycerine
famotidine and domperidone
faropenem medoxomil
nedosiran
fluconazole/ornidazole/azithromycin
ebastine/montelukast
eberconazole
dienogest/estradiol valerate
ambroxol/salbutamol
benzoic acid/salicylic acid/ichthammol/ triamcinolone acetonide
desloratadine/ambroxol
dexibuprofen/paracetamol
atorvastatin/ramipril
diastase
diastase and simethicone
diazepam and propranolol
dexrabeprazole / domperidone
dexrabeprazole
dexketoprofen /paracetamol
beta carotene/vitamin C/minerals
aloe vera gel/urea
aloe vera gel/glycerine
alpha-lipoic acid/benfotiamine/chromium/folic acid/mecobalamin / vit b6
alprazolam/propranolol
alprazolam /sertraline
ibuprofen/dextropropoxyphene
ambroxol/cetirizine/phenylephrine/ guaiphenesin/menthol
dextropropoxyphene/dexchlorpheniramine maleate/bromhexine
promegestone
batroxobin
bencyclane
benfluorex
acetylpheneturide
abarelix
abetimus
naftidrofuryl
nalorphine
oxiracetam
letosteine
lafutidine
leuprorelin
levodropropizine
glutaral
losartan/ramipril
gallopamil
lanatoside c
lauromacrogol
gestodene
aceclofenac/methyl salicylate/menthol/linseed oil/capsaicin
aceclofenac/paracetamol/tizanidine
alginic acid/magaldrate/simethicone
aceclofenac/paracetamol
aceclofenac/rabeprazole
alginic acid
pantoprazole and domperidone
urokinase
rimiterol
olanzapine/fluoxetine
normethadone/hydroxyephedrine
myrtol
moxonidine
propylhexedrine
sodium hypochlorite solution
sodium chloride/sodium citrate
Hepatitis B Vaccine (Recombinant [Adjuvanted])
Hepatitis B Vaccine (Recombinant)
aceclofenac and serratiopeptidase
levosulpiride
niaprazine
tromantadine
trimetazidine
vinburnine
mizoribine
molgramostim
mosapride
eugenol
tolperisone
etamsylate
etynodiol
mizolastine
metenolone
reproterol
rebamipide
mephenoxalone
metandienone
furosemide/spironolactone
hydroxycarbamide
tenonitrozole
fenoverine
fenquizone
tiapride
tibolone
furazolidone
furosemide & amiloride
fosfestrol
fluclorolone
flubendazole
tertatolol
tetracosactide
tetryzoline
tolciclate
trapidil
troxipide
temoporfin
telbivudine
teprenone
hexamidine
mebhydrolin
mepartricin
fencamfamin
medazepam
theodrenaline
thiamazole
thiocolchicoside
psilocybin
veralipride
pyritinol
opipramol
oprelvekin
betamethasone + gentamicin
betamethasone + neomycin
betamethasone + salicylic acid
oxedrine
bopindolol
orgotein (investigational)
oxaceprol
ormeloxifene
bevantolol
bifemelane
clebopride
demoxytocin
cicletanine
cefsulodin
chlortalidon
sisomicin
somatrem
carbazochrome
caroverine
cathine
ipriflavone
isepamicin
silymarin
simethicone
sermorelin
diloxanide
dimethindene
diosmin/hesperidin
calamine
canrenone
captodiame
imidapril
cefetamet
cefodizime
cefoperazone + sulbactam
ivermectin + albendazole
serrapeptase
bromisoval
beraprost
pridinol
proglumide
bamipine
barnidipine
bamifylline
benzbromarone
betamethasone/fusidic acid
para-chlorophenol
pantethine
nomifensine
pemoline
parnaparin
pentolinium
nialamide
novobiocin
nicergoline
octocrylene
octisalate
oftasceine
oxolamine
oxyphencyclimine
penfluridol
pentoxyverine
phenoxymethylpenicillin
picloxydine
pilsicainide hydrochloride
piperazine
pirarubicin
policresulen
prifinium bromide
prethcamide
pristinamycin
pirenzepine
piribedil
pimethixene
pargyline
phosphatidyl choline
phthalylsulfathiazole
phytomenadione
pranlukast
pinazepam
oxyphenonium
noxytiolin
periciazine
pethidine
phenindamine
histidine
isoleucine
proline
lauric acid
lymecycline
hypromellose
abiraterone acetate and niraparib
ichthammol
levamisole
naftazone
nefopam
oxprenolol
oxybuprocaine
elranatamab-bcmm
lapyrium
isoaminile
iotrolan
mazindol
masoprocol
lypressin
meradimate
molsidomine
monobenzone
mequinol/gluconolactone/ lactobionic acid/ arbutin
medifoxamine
mebutamate
metergoline
methantheline
methdilazine
metocurine
micronomicin
metaraminol
mephenesin
menadione
medrysone
metixene
levobetaxolol
guaiacol glycerol ether
eucalyptol
sodium tetradecyl sulfate
sugammadex
carbetocin
certoparin
chlorcyclizine/pseudoephedrine
cephapirin
indecainide
iobitridol
iomeprol
chlorphenesin
msud analog
msud maxamum
iceland moss
glutethimide
hexachlorophene
haloprogin
deferoxamine
ethchlorvynol
dexpanthenol topical
etilefrine
deslanoside
carbocromen
diazolidinylurea
dibenzepin
etofamide
guanoxan
halazepam
guanadrel sulfate
dapiprazole
soapwort
debrisoquine
l-tryptophan
chlormerodrin
chlorquinaldol
cetrimonium
carbocisteine
chlorcyclizine/codeine
technetium Tc-99m tetrofosmin
technetium Tc-99m disofenin
technetium Tc-99m gluceptate
technetium Tc-99m labeled red blood cells
amylmetacresol/dextromethorphan hydrobromide
anileridine phosphate
pyrethrins
pyrantel pamoate
quinagolide
spiramycin
standard hyperkalemic cardioplegia solution
technetium tc-99m mertiatide
technetium tc-99m medronate
bemotrizinol / bisoctrizole
benfotiamine
bemotrizinol + titanium dioxide + zinc oxide
technetium Tc-99m oxidronate
technetium Tc-99m pentetate
technetium Tc-99m pyrophosphate
benziodarone
octinoxate/bisoctrizole
bicisate dihydrochloride
technetium Tc-99m bicisate
norelgestromin/ethinyl estradiol
norgestimate/ethinyl estradiol
ximelagatran (investigational)
xamoterol
trioxsalen
poly-urea urethane
rilmenidine
pemirolast
oxitriptan
beclomethasone, intranasal
thimerosal
camphor gel
camphor
mumps virus vaccine, live
rubella virus vaccine, live
aluminum chloride (dental)
alum irrigation
framycetin, phenylephrine, and gramicidin
ombitasvir, paritaprevir, ritonavir, and dasabuvir
olipudase alfa
etonogestrel/ethinyl estradiol
mycophenolate
fluoroestradiol F 18
donor organ cardioplegia solution
fluciclovine F 18
fusidic acid (ophthalmic)
fusidic acid and hydrocortisone
framycetin, dexamethasone, and gramicidin
fludeoxyglucose F-18
fluorouracil/salicylic acid
indium In-111 oxyquinoline
indium In-111 pentetreotide
indium In-111 capromab pendetide
lusutrombopag
mitomycin (ophthalmic)
mifepristone and misoprostol
minoxidil (systemic)
methyl aminolevulinate (topical)
methyl folate, methylcobalamin, and acetylcysteine
ciclesonide/formoterol/tiotropium
nedocromil (Oral Inhalation)
batefenterol (Investigational)
neostigmine and glycopyrrolate
nepafenac ophthalmic
netupitant/palonosetron
meperidine and promethazine
mepivacaine and levonordefrin
maltodextrin
medical cannabis
medium chain triglycerides
mometasone/glycopyrrolate (glycopyrronium)/ indacaterol
moxifloxacin ophthalmic
neomycin/fluocinolone
nadroparin
iodine I-125 iothalamate
amikacin liposome (oral inhalation)
bupivacaine liposome
natamycin
lopinavir and ritonavir
lysine
macitentan and tadalafil
mitomycin pyelocalyceal
moclobemide
mometasone and indacaterol
efinaconazole
blue-green algae
indocyanine green
follitropin beta
lumasiran
glycerin/lidocaine
edrophonium/atropine
indigo carmine
lutropin alfa
instant glucose/intravenous dextrose
iobenguane I-123
ixekizumab
isosulfan blue dye
levofloxacin ophthalmic
levonorgestrel oral/ferrous bisglycinate/ ethinylestradiol
ethinyl estradiol/levonorgestrel transdermal
hydroquinone
hydroxypropyl methylcellulose
icodextrin
lipid emulsion (soybean, medium-chain triglyceride, olive, and fish oils; [SMOF])
iodinated I 125 albumin
iodinated I 131 albumin
lipid emulsion (plant oil-based)
levonorgestrel intrauterine
levonorgestrel/ethinyl estradiol
lactic acid and sodium-PCA
lactated Ringer solution
ketotifen (systemic)
lanolin
leuprolide and norethindrone
levodopa and benserazide
gonadorelin acetate
hemodialysis solutions
nirsevimab
gentian violet
gallium ga-68 dotatate
fusidic acid and betamethasone
gallium citrate Ga-67
gadopentetate dimeglumine
gadofosveset
follitropin delta
follitropin alfa and lutropin alfa
follitropin alfa
rocatinlimab
grass pollens allergen extract
flotufolastat F18
fluorescein ophthalmic
barium
balanced salt solution
air polymer type A intrauterine device
clodronate
bentoquatam
clobetasone
alfacalcidol
citric acid/glucono-delta-lactone/magnesium carbonate
benzoin
desirudin
immune globulin IV (IGIV)
dequalinium
pseudoephedrine/desloratadine
clofedanol
cyproterone and ethinyl estradiol
dextranomer and hyaluronic acid or derivatives
diatrizoate meglumine and diatrizoate sodium
glucosamine sulfate, chondroitin sulfate and Msm
squill
gotu kola
blessed thistle
bitter melon
apraclonidine
chlophedianol/dexbrompheniramine/pseudoephedrine
wild jujube
chitosan
cilazapril/hydrochlorothiazide
dexbrompheniramine and phenylephrine
diethylene triamine penta-acetic acid
dexchlorpheniramine and pseudoephedrine
lily of the valley
diflucortolone
corydalis
lemon balm
MSM
calcium polystyrene sulfonate
caprylidene
peppermint oil
efavirenz/lamivudine/tenofovir DF
emtricitabine/tenofovir DF /efavirenz
dutasteride/tamsulosin
milk thistle
centaury
horseweed
lycopus
agrimony
alfalfa
kava
cetrorelix
cetylpyridinium
chlophedianol and dexbrompheniramine
betahistine
choline C-11
boric acid vaginal suppository
aluminum acetate
aluminum chloride hexahydrate
14-C urea breath test
absorbable collagen
valoctocogene roxaparvovec-rvox
amlodipine and celecoxib
aspirin and omeprazole
azilsartan and chlorthalidone
landiolol (Pending FDA approval)
isosorbide dinitrate/hydralazine
losartan/hydrochorothiazide
udenafil
dextromethorphan/quinidine
onasemnogene abeparvovec
orphenadrine/aspirin/caffeine
Trace elements
sodium phenylbutyrate/ taurursodiol
fish oil triglycerides
infant formula
glutamine
chloroquine phosphate
afatinib
quinidine gluconate
methylergonovine
prothrombin complex concentrate, human
BCG intravesical live
capivasertib
cedazuridine
carbonyl iron
iron dextran complex
lovotibeglogene autotemcel (FDA Approval Pending)
sodium benzoate/sodium phenylacetate
mineral oil otic
zolmitriptan transdermal
midazolam intranasal
fosinopril/hydrochlorothiazide
caplacizumab
arginine
sodium phenylbutyrate
meloxicam/rizatriptan
manganese
acetaminophen/pamabrom/pyridoxine
varicella zoster immune globulin, human
amitriptyline/perphenazine
narsoplimab (Pending FDA Approval)
amlodipine/perindopril
imiglucerase
canagliflozin/metformin
tafamidis meglumine
somatrogon-ghla
glimepiride/rosiglitazone
becaplermin
lithium
loxapine inhaled
nicotine transdermal
tixagevimab and cilgavimab (Investigational)
muromonab CD3
ansuvimab
coal tar bath products
fibrin sealant
arimoclomol (FDA Approval Pending)
varenicline intranasal
aducanumab
oxycodone/naloxone
ritlecitinib
sodium polystyrene sulfonate
calcipotriene/betamethasone
calcium hydroxylapatite
cantharidin topical
doxepin cream
clocortolone
formaldehyde topical
sodium sulfide topical
collagenase
selegiline transdermal
foscarbidopa/foslevodopa (FDA approval pending)
saxagliptin/metformin
linagliptin/metformin
linzagolix (FDA approval pending)
efgartigimod/hyaluronidase SC
Elamipretide
rozanolixizumab
diazoxide
glimepiride/pioglitazone
cipaglucosidase alfa
dihydroergotamine intranasal
delandistrogene moxeparvovec
beremagene geperpavec
hyaluronic acid and derivatives
hyaluronic acid, non-animal stabilized
eplontersen (FDA Approval Pending)
nitric oxide gas
sodium phenylbutyrate and taurursodiol
treprostinil SC
viltolarsen
albuterol/ipratropium
budesonide inhaled
budesonide rectal
palovarotene
sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol
amino acids mixture
aminobenzoate potassium
elivaldogene autotemcel
naproxen and sumatriptan
sumatriptan intranasal
alglucerase
metformin/rosiglitazone
ertugliflozin/metformin
elosulfase alfa
calcium carbonate/magnesium hydroxide
starch suppository
abicipar pegol (FDA Approval Pending)
riboflavin 5′-phosphate ophthalmic
povidone ophthalmic
glycerin oropharyngeal
dimethicone topical
menthol topical, dimethicone topical
pramoxine topical, menthol topical and dimethicone topical
phosphorated carbohydrate
brilliant blue G ophthalmic
brolucizumab intravitreal
purified water, ophthalmic
hydroxyethyl cellulose ophthalmic
ranibizumab intravitreal implant
sodium chloride hypertonic, ophthalmic 
cetirizine ophthalmic
phentolamine ophthalmic
ganciclovir ophthalmic
triamcinolone intravitreal
ocriplasmin intravitreal
atoltivimab/maftivimab/odesivimab
pegcetacoplan intravitreal
triamcinolone acetonide extended-release injectable suspension
tobramycin/loteprednol ophthalmic
2-octyl cyanoacrylate
vitamins A & D topical
diphenhydramine/allantoin topical
pyrethrins/piperonyl butoxide
lodoxamide ophthalmic
obeticholic acid
fluocinolone intravitreal implant
sincalide
linaclotide
nedocromil ophthalmic
cysteamine ophthalmic
avacincaptad pegol intravitreal
azelastine ophthalmic
bacitracin ophthalmic
propylene glycol ophthalmic
rimexolone ophthalmic
metoclopramide intranasal
mirikizumab
netarsudil ophthalmic
cenegermin
dexamethasone ophthalmic insert
prednisolone ophthalmic
phenylephrine and cocoa butter rectal
phenylephrine and witch hazel topical
phenylephrine, pramoxine, glycerin and petrolatum rectal
bisacodyl rectal
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
hyoscyamine spray
methenamine/methylene blue/ hyoscyamine/ sodium phosphate monobasic/ phenyl salicylate
phenylephrine
chlorophyll
castor oil
cholic acid
phenol oropharyngeal
articaine/epinephrine
antithymocyte globulin equine
aluminum hydroxide/magnesium trisilicate
methenamine/hyoscyamine
hydrocortisone topical/pramoxine topical
sodium fluoride topical
mesna
C1 esterase inhibitor recombinant
menthol and pectin
menthol oropharyngeal
pectin oropharyngeal
gepirone
Goldenseal
polyethylene glycol and electrolytes
polyethylene glycol/electrolytes/sodium ascorbate/ascorbic acid
brompheniramine/pseudoephedrine/dextromethorphan
brompheniramine phenylephrine
acetaminophen/doxylamine/phenylephrine
doxylamine/acetaminophen/pseudoephedrine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
eslicarbazepine
fluticasone and salmeterol
codeine, acetaminophen, butalbital and caffeine
codeine, chlorpheniramine and phenylephrine
iodine
povidone iodine
butalbital/aspirin/caffeine/codeine
polyethylene glycol 400/propylene glycol ophthalmic 
pegvaliase
amivantamab
iopamidol
codeine and pseudoephedrine
emtricitabine, rilpivirine, tenofovir DF
penicillin G aqueous
miconazole topical
miconazole vaginal
ciprofloxacin inhaled (Pending FDA approval)
ceftazidime/avibactam
ceftolozane/tazobactam
aztreonam inhalation
amphotericin B cholesteryl sulfate
miconazole oral
elvitegravir/cobicistat/emtricitabine/tenofovir DF
isavuconazonium sulfate
dapivirine intravaginal (FDA Approval Pending)
lamivudine/raltegravir
codeine/triprolidine/pseudoephedrine
cadexomer iodine
brompheniramine/pseudoephedrine
codeine/acetaminophen
codeine/guaifenesin
beclomethasone inhaled
epoetin beta/methoxy polyethylene glycol
voreloxin(Orphan Drug)
rociletinib
pitcher plant
phosphatidylserine
telotristat ethyl
copper CU 64 dotatate
urea topical
exenatide subdermal implant
asenapine transdermal
ethiodized oil
urea oral
miglustat
acalisib(Investigational)
acetophenazine
guggul
aceneuramic acid
mestranol/norethindrone
reishi
lactitol
vonoprazan fumarate
motherwort
silver nitrate
salicylic acid/sulfur shampoo
salicylic acid topical
ketorolac ophthalmic
ketoconazole topical
Japanese encephalitis virus vaccine
dibucaine topical ointment
ketorolac intranasal
ketorolac/phenylephrine ophthalmic
rotavirus oral vaccine, live
guarana
hops
krill oil
salicylic acid/coal tar shampoo
sufentanil SL
pancrelipase
passion flower
pepdite one plus
nivolumab and relatlimab
relatlimab (Pending FDA Approval)
benzalkonium chloride/benzocaine
ketotifen, drug-eluting contact lens
calcitriol topical
oxymetazoline topical
alclometasone topical
capsaicin topical
diclofenac/misoprostol
diclofenac ophthalmic
diclofenac topical
pramoxine/calamine topical
veverimer
tolazoline
olopatadine ophthalmic
lutetium lu 177-dota-tate
lutetium lu 177 vipivotide tetraxetan
strontium 89 chloride
interferon alfa n3
lutetium Lu 177- Diethylenetriamine Pentaacetic acid-omburtamab (FDA Approval Pending)
samarium sm 153 lexidronam
cytomegalovirus immune globulin (CMV IG)
antithymocyte globulin rabbit
inolimomab (Pending FDA Approval)
olopatadine intranasal
olopatadine intranasal/mometasone, intranasal
benzocaine/butamben/tetracaine topical
antipyrine/benzocaine/phenylephrine
dyclonine/menthol
surufatinib
fruquintinib
dostarlimab
hepatitis B immune globulin (HBIG)
remestemcel-L
benzocaine/menthol oropharyngeal
interferon beta 1b
tetracaine/oxymetazoline intranasal
benzocaine oropharyngeal
benzalkonium chloride/menthol/petrolatum topical
inamrinone
alpha 1 proteinase inhibitor
potassium bicarbonate/potassium citrate
potassium phosphate/sodium acid phosphate
asparaginase Erwinia chrysanthemi recombinant
motixafortide
pegloticase
etesevimab
Rho(D) immune globulin
tetanus immune globulin (TIG)
reltecimod (pending FDA approval)
avasopasem
trimethoprim/polymyxin B ophthalmic
naphazoline ophthalmic
sulfacetamide topical
sirolimus intravitreal (pending FDA approval)
sirolimus protein bound
sirolimus topical
glycopyrronium tosylate topical
sofpironium
olmesartan, amlodipine and hydrochlorothiazide
dovitinib (Pending FDA Approval)
epinephrine inhaled
quizartinib (Pending FDA Approval)
ranibizumab intravitreal injection
sodium hyaluronate
bacitracin and lidocaine topical
brimonidine topical
benzoyl peroxide and tretinoin topical
talquetamab
betrixaban
acetaminophen/caffeine/pyrilamine
fentanyl transmucosal
bacitracin topical
buprenorphine,long-acting injection
buprenorphine buccal
nalmefene intranasal
sulbactam/durlobactam
metronidazole topical 
daratumumab/hyaluronidase
glofitamab
rituximab-hyaluronidase
drospirenone/ethinyl estradiol/levomefolate
loncastuximab tesirine
ingenol mebutate topical
momelotinib
trastuzumab/deruxtecan
trastuzumab/hyaluronidase
trastuzumab duocarmazine
lifileucel
umbralisib
eflornithine/sulindac
cytarabine/daunorubicin liposomal
doxorubicin liposomal
epcoritamab
lanadelumab  
esomeprazole/naproxen 
terbinafine topical
ravulizumab
clotrimazole topical
choline magnesium trisalicylate
tacrolimus ointment
mechlorethamine topical
donislecel
pozelimab (Pending FDA Approval)
human rabies immune globulin (HRIG)
melphalan flufenamide
sintilimab (Pending FDA Approval)
oportuzumab monatox (Pending FDA Approval)
sotorasib
irinotecan liposomal
sulfur topical
silver sulfadiazine
capsaicin transdermal
sutimlimab
tretinoin topical
acetaminophen rectal
menthol topical
naftifine
oatmeal, colloidal topical
oxiconazole
methylsalicylate/menthol topical
C1 inhibitor human
lifitegrast ophthalmic
prednisolone/sulfacetamide ophthalmic
mannitol inhalation
ofloxacin otic
petrolatum & mineral oil topical
clascoterone topical
gefapixant (Pending FDA Approval)
colesevelam
technetium Tc 99m succimer
nebivolol/valsartan
ciprofloxacin/fluocinolone acetonide, otic
finafloxacin otic
magnesium hydroxide/mineral oil
phenylephrine/mineral oil/petrolatum rectal
carbamide peroxide oral
atropine ophthalmic
sodium sulfacetamide/sulfur
sulfacetamide ophthalmic
lucinactant
benzonatate
besifloxacin ophthalmic
benzhydrocodone/acetaminophen
beractant
trimagnesium citrate anhydrous
vitamin b2
carbamide peroxide otic
mineral oil topical
ethyl alcohol intranasal
boric acid/alcohol otic
absorbable gelatin compressed sponge, USP
absorbable gelatin sponge, USP
vincristine liposomal
technetium Tc 99m albumin aggregated injection
metaproterenol
budesonide inhaled/formoterol/glycopyrrolate inhaled
epinephrine racemic
umeclidinium bromide/vilanterol inhaled
indacaterol, inhaled/glycopyrrolate inhaled
betaine  
laronidase 
estrogens esterified/methyltestosterone            
cerliponase alfa
ertugliflozin/sitagliptin
hawthorn
shepherd’s purse
thiamine
naphazoline/glycerin ophthalmic
oxymetazoline ophthalmic
dorzolamide
dexamethasone intraocular
dexamethasone/ciprofloxacin
dexamethasone ophthalmic
metipranolol ophthalmic
timolol ophthalmic
boron
fezolinetant
pegunigalsidase alfa-iwxj
biotin
pantothenic acid
silicon
sodium acid phosphate
hypochlorous acid topical
methenamine/sodium acid phosphate
aviptadil 
bremelanotide
glucagon intranasal
metformin and repaglinide
bai ji
pau d’arco
juzentaihoto
mistletoe
quercetin
rosemary
sheng di huang
chasteberry
maitake
grapefruit
lentinan
juniper
nettle
parsley
rose hips
tongkat ali
horny goat weed
damiana
yohimbe
insulin NPH
aprocitentan
noni Juice
sodium iodide I-131
green tea
sea cucumber
wheat germ extract
fenofibrate micronized 
rogisen
danshen
lutein
witch hazel
dextroamphetamine transdermal
amphetamine/dextroamphetamine
hoodia
kolanut
boswellia
opuntia ficus indica
lavender
nadh
tea tree oil
metformin/sitagliptin 
dapagliflozin/ metformin/saxagliptin  
antihemophilic factor recombinant
inclisiran
bempedoic acid/ezetimibe
volanesorsen
omega 3 carboxylic acids
pericyazine
levomepromazine (methotrimeprazine)
betaxolol ophthalmic
respiratory syncytial virus vaccine, adjuvanted
phenylephrine hydrochloride and tropicamide ophthalmic
alirocumab
neomycin/polymyxin B/gramicidin ophthalmic
factor IX
gentamicin topical
ansofaxine (Pending FDA Approval)
zuranolone
factor IX, recombinant
factor IX complex
factor XIII A-subunit, recombinant
factor X, human
mesalamine rectal
etrasimod
anti-inhibitor coagulant complex
factor IX, recombinant/albumin fusion protein
fibrinogen, human
aminocaproic acid
metyrosine
nonoxynol-9 vaginal
progesterone intravaginal gel
ipecac syrup
botulinum antitoxin, heptavalent
pentetate calcium trisodium
crotalidae polyvalent immune FAB (ovine)
dehydrated alcohol injection
gold sodium thiomalate (Discontinued)
lactic acid/citric acid/potassium bitartrate vaginal
von Willebrand factor, recombinant
luspatercept
digoxin immune FAB (Antidote)
crotalidae immune FAB (equine)
magnesium (Antidote)
pyridoxine (Antidote)
edetate calcium disodium
albumin IV
nitroglycerin sublingual
obiltoxaximab
anthrax immune globulin
nitroglycerin topical
dextrose
nesiritide
estradiol vaginal
bazedoxifene/conjugated estrogens
botulism immune globulin iv
amoxicillin/omeprazole/rifabutin
synthetic human angiotensin II
nitroglycerin IV
nitroglycerin translingual
nitroprusside sodium
tetrahydrozoline/zinc sulfate/hypromellose ophthalmic
sodium citrate/citric acid
pemetrexate
Methicillin
plasminogen 
acai
american ginseng
cordyceps
tramadol/acetaminophen
belladonna alkaloids/phenobarbital
erythromycin topical/benzoyl peroxide
glucosamine sulfate
panax ginseng (suppl/herb)
tolnaftate
sulopenem etzadroxil/probenecid
sulfur hexafluoride
sotrovimab
arbaclofen
rifampin/isoniazid
clindamycin /tretinoin topical
benzoyl peroxide/clindamycin topical
apremilast
antivenins, centuroides (scorpion)
bamlanivimab and etesevimab
vilobelimab
gadobenate
pentosan polysulfate sodium
methylsalicylate/menthol/camphor topical
antivenin, black widow spider
benzoyl peroxide and hydrocortisone
clindamycin topical
isometheptene, dichloralphenazone and acetaminophen
acetaminophen and phenyltoloxamine
erythromycin topical
erythromycin ophthalmic
alpha hydroxy acids, topical
buprenorphine transdermal
butalbital/acetaminophen/caffeine
buprenorphine/samidorphan
buprenorphine subdermal implant
celecoxib/tramadol
drospirenone/ethinyl estradiol
resorcinol/sulfur
eflornithine
rifampin/isoniazid/pyrazinamide
tofersen
devil’s claw
ticarcillin/clavulanate
atropine/pralidoxime
aprepitant
suramin
phenelzine
artichoke
american dogwood
attapulgite
atlantic cedar
axalimogene filolisbac
sodium thiosulfate & sodium nitrite
ataluren
omidubicel-onlv
capsicum
ginger
cryoprecipitate
bictegravir/emtricitabine/tenofovir DF
emtricitabine/tenofovir DF
fo-ti
siberian ginseng
granulocytes
zinc substituted heme C
zinc trihydroxide
ashwagandha 
cat’s claw
glandular products
SAMe
shark cartilage
altovis
feverfew
horse chestnut
magnesium aspartate
octacosanol
pleurisy root
star anise
butterbur
elderberry
licorice (Suppl/herb)
aconite
pentetate zinc trisodium
menthol topical/zinc oxide topical
corn-starch/kaolin/zinc oxide topical
5-hydroxytryptophan (5-htp)
butcher’s broom
articulin
bearberry
goldenrod
progesterone, natural
black cohosh
wild yam
cranberry
dong quai
phytoestrogens
norethindrone
false Unicorn Root
raspberry Leaf
asafoetida
turmeric
dehydroepiandrosterone (DHEA)
hyaluronan
aliskiren/amlodipine
octreotide (Antidote)
tranexamic acid injection
duocal
neocate infant formula
pediatric Eo28
aloe
red clover
propolis
androstenedione
heartsease
comfrey
bilberry
chamomile
eyebright
calendula
sage
yucca
polypody
odevixibat
vinpocetine
olanzapine/samidorphan
creatine
yerba mate
spesolimab
azficel-T
tiludronate
estetrol and drospirenone
pseudoephedrine/fexofenadine
lincomycin
neomycin oral
fluocinolone acetonide, otic
tretinoin/ hydroquinone/ fluocinolone
halobetasol topical
hydrocortisone/iodoquinol
penicillin G procaine /penicillin G benzathine
hydrocortisone probutate topical
colistin/neomycin/hydrocortisone/thonzonium otic
ebola zaire vaccine
hepatitis a/b vaccine
vibegron
lindane
nystatin topical
respiratory syncytial virus (RSV) vaccine
chikungunya vaccine, live
tenecteplase
reteplase
anthrax vaccine adsorbed, adjuvanted
meningococcal ABCWY pentavalent vaccine
eculizumab
cholestyramine
tinzaparin
taurolidine/citrate/heparin
protein C concentrate
antithrombin alfa
antithrombin III
multivitamins, vision
ibuprofen/chlorpheniramine/pseudoephedrine
acetaminophen/ibuprofen
ibuprofen/pseudoephedrine
paclitaxel protein-bound
acetic acid vaginal
acetic acid otic
hydrocodone/ ibuprofen
methyl salicylate / isopropanol/ citronellyl acetate/ citric acid
ibuprofen and phenylephrine
acetylcysteine (Antidote)
iron/folic acid/vitamin/mineral
iobenguane I-131
dolutegravir/rilpivirine
chlorhexidine topical
chlorhexidine oral
thyroid desiccated
proparacaine ophthalmic
podophyllum resin
phendimetrazine
phenoxybenzamine
polidocanol
phentermine and topiramate
piflufolastat F18
piperacillin/tazobactam
prednisolone and gentamicin ophthalmic
promethazine and codeine
poractant alfa
protamine sulfate
aflibercept intravitreal
prednicarbate
promethazine/dextromethorphan
codeine, phenylephrine, and promethazine
potassium phosphate
glatiramer acetate
gentamicin (Ophthalmic)
leniolisib
rezafungin
fluorometholone
dalfampridine
hydrocortisone topical 
empagliflozin and linagliptin
triamcinolone topical
minocycline topical
minocycline dental
ketotifen ophthalmic
darunavir and cobicistat
lidocaine topical
neomycin/polymyxin B/bacitracin/lidocaine (OTC)
lidocaine/ hydrocortisone
lidocaine anesthetic
lidocaine ophthalmic
lidocaine/tetracaine
desonide
dabigatran
fexofenadine
fluoride
decitabine and cedazuridine
dasiglucagon
hydroxypropyl cellulose ophthalmic
epoetin alfa
ibritumomab tiuxetan
trimethobenzamide
dexamethasone/ tobramycin
tafasitamab
valacyclovir
mebendazole
levoleucovorin
flaxseed
germanium
glutathione
lycopene
pygeum
horseradish
ziv-aflibercept
micafungin
trofinetide
taliglucerase alfa
tildrakizumab
sulopenem (Pending FDA Approval)
thyrotropin alfa
birch
thrombin, topical
tivozanib
tafluprost
methohexital
urea and hydrocortisone
unoprostone ophthalmic
trihexyphenidyl
ezetimibe
evolocumab
trifluridine and tipiracil
methenamine
misoprostol
miltefosine
rimantadine
maralixibat
coenzyme Q10
chlorella
garlic
forskolin
zavegepant
menotropins
margetuximab
meprobamate
melarsoprol
evening primrose oil
lemongrass
molindone
fenugreek
phytosterols
red yeast rice
uridine triacetate
tropicamide
incobotulinumtoxinA
Grape Seed Extract
carbachol ophthalmic
cosyntropin
cyclopentolate and phenylephrine
carteolol ophthalmic
pentazocine/naloxone
pentazocine/acetaminophen
casimersen
carisoprodol, aspirin, and codeine
carisoprodol
carboprost tromethamine
flurandrenolide

lonafarnib +

may enhance the serum concentration of CYP3A4 inhibitors

curcumin

may enhance the serum concentration of CYP3A4 inhibitors

glecaprevir

may enhance the serum concentration of CYP3A4 inhibitors

caspofungin

may enhance the serum concentration of CYP3A4 inhibitors

may enhance the serum concentration of CYP3A4 inhibitors

grapefruit

It may enhance the effect when combined with grapefruit by CYP3A4 metabolism

maralixibat

may enhance the concentration of serum when combined with lonafarnib

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

mibefradil

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

citalopram

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

efavirenz

lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors

nafcillin

When naficillin combines with lonafarnib, nafcillin will decrease the effect of action of lonafarnib by affecting enzyme CYP3A4 metabolism.

ivosidenib

when both drugs are combined, there may be a decreased effect of lonafarnib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  

lapatinib

lapatinib increases the effect of lonafarnib by altering the intestinal or hepatic CYP3A4 enzyme metabolism

bicalutamide

when both drugs are combined, there may be an increased effect of Lonafarnib by affecting hepatic or intestinal enzyme CYP3A4 metabolism 

pexidartinib

pexidartinib decreases the effect or level of lonafarnib by altering the intestinal/hepatic CYP3A4 enzyme metabolism

osilodrostat

may enhance the serum concentration of CYP3A4 inhibitors

amlodipine/telmisartan

may enhance the serum concentration of CYP3A4 inhibitors

may enhance the serum concentration of CYP3A4 inhibitors

abametapir

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

amiodarone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

amobarbital

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

apalutamide

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

butabarbital

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

butalbital

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

carbamazepine

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

ceritinib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

doxycycline

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

dronedarone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

efavirenz

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

elagolix

It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism

itraconazole

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

ivacaftor

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

voxelotor

may enhance the serum concentration of CYP3A4 Inhibitors

ifosfamide

when both drugs combine lonafarnib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.

cyclophosphamide

cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.

alpelisib

when both drugs are combined, there may be a decreased level of serum concentration of lonafarnib   

brentuximab

the lonafarnib, interacting with brentuximab, shows increased effect by altering the intestinal or hepatic CYP3A4 enzyme metabolism.

lenvatinib

the effect of lonafarnib is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism. Avoid or take an alternate drug.

enzalutamide

CYP3A strong enhancers of the small intestine may reduce the bioavailability of lonafarnib

regorafenib

it will increase the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism

ribociclib

it increases the concentration of lonafarnib in serum

ruxolitinib

it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism

methimazole

methimazole increases the effect of lonafarnib by altering intestinal or hepatic metabolism

danazol

danazol increases the effect or level of lonafarnib by altering intestinal or hepatic CYP3A4 enzyme metabolism

zonisamide

may increase the level of zonisamide by affecting hepatic enzyme CYP3A4 metabolism

elagolix

OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum

OATP1B1/1B3 inhibitors increase the concentration of elbasvir and grazoprevir in the serum

voxilaprevir

OATP1B1/1B3 inhibitors increase the concentration of voxilaprevir in the serum

may enhance the serum concentration of elbasvir/grazoprevir

abemaciclib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

acalabrutinib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

acetaminophen

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

buspirone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

busulfan

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

cabozantinib

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

calcifediol

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

drospirenone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

elacestrant

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

ergotamine

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

losartan

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

lurasidone

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

mefloquine

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

asunaprevir

OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum

OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of elbasvir and grazoprevir in the serum

revefenacin

BCRP/ABCG2 inhibitors increase the concentration of pazobanib in the serum

taurursodiol

OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of taurursodiol in the serum

leniolisib

it increases the concentration of OATP1B1/1B3 substrates in the serum

zuclopenthixol

it may diminish the metabolism when combined with zuclopenthixol

epcoritamab

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

adagrasib

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

imiquimod topical

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

fluorouracil topical

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

peginterferon alfa-2b

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

dexrabeprazole

When dexrabeprazole and lonafarnib is used together, this leads to reduction in the dexrabeprazole’s metabolism

carbimazole

It may enhance the risk of adverse effects when combined with Metabolic agents

potassium perchlorate

It may enhance the risk of adverse effects when combined with Metabolic agents

simvastatin

lonafarnib: it may enhance the serum concentration of simvastatin

topotecan

when both drugs are combined, there may be a reduced excretion rate of topotecan and result in an elevated level of serum concentration  

daunorubicin

increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter

idarubicin

increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter

voclosporin

may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates

brincidofovir

OATP1B1/1B3 inhibitors increase the concentration of brincidofovir in the serum

eluxadoline

OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum

pretomanid

may increase the serum concentration of OAT1/3 substrates

atogepant

It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

duvelisib

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

edoxaban

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

eletriptan

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

tacrolimus

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

talazoparib

It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter

valrubicin

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

epirubicin

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

mitoxantrone

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

mitomycin

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

paclitaxel/encequidar

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

paclitaxel

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

cabazitaxel

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

docetaxel

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

sacituzumab govitecan

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

topotecan

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

etoposide

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

irinotecan

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

teniposide

it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates

Actions and Spectrum:

In progeria, a rare genetic disorder that causes premature aging, lonafarnib has been shown to improve survival and reduce the incidence of certain complications associated with the disease.

In HDV infection, lonafarnib has been shown to inhibit the replication of the virus, which can lead to improved results for patients with this difficult-to-treat condition.

Frequency defined

>10%

Infection (78%)

Abdominal pain (48%)

Electrolyte abnormalities (43%)

Nausea (56%)

Headache (37%)

Musculoskeletal pain (48%)

Constipation (22%)

Decreased weight (37%)

Myelosuppression (35%)

Increased ALT (27%)

Diarrhea (81%)

Increased AST (35%)

Cerebral ischemia (11%)

Decreased appetite/anorexia (53%)

Ocular changes (24%)

Pyrexia (14%)

Hypertension (29%)

Rash (11%)

Rhinitis (19%)

Epistaxis (21%)

Fatigue (51%)

Upper respiratory tract infection (51%)

Cough (33%)

Vomiting (90%)

Decreased blood bicarbonate (33%)

1-10%

Dehydration (5%)

Flatulence (6%)

Pruritus (8%)

Mucositis (8%)

Depressed mood (5%)

Black Box Warning:

Contraindication/Caution:

Contraindication

lonafarnib has several contraindications, which means the drug should not be used on specific individuals. These include:

Hypersensitivity: lonafarnib is contraindicated in individuals with known hypersensitivity/allergy to the drug or its components.
Pregnancy and breastfeeding: lonafarnib may cause harm to a developing fetus and should not be generally used during pregnancy. It is also unknown whether the drug is excreted into the breast milk, so it should not be used while breastfeeding.
Severe hepatic impairment: lonafarnib is contraindicated in individuals with severe hepatic impairment, as it may exacerbate liver damage and enhance the risk of liver toxicity.
Use with certain medications: lonafarnib may interact with certain medications, such as potent CYP3A inhibitors and inducers, and should not be combined.
Children: The safety and effectiveness of lonafarnib have yet to be established in children under 18 years of age; it is generally not recommended for use in this population.

It is essential to discuss all current medications and medical conditions with a healthcare provider before taking lonafarnib to determine whether it is appropriate and safe for use.

Caution

Several cautions should be considered before taking lonafarnib. These include:

Hepatic impairment: lonafarnib should be used cautiously in individuals with mild hepatic impairment, as the drug may increase the risk of liver toxicity.
Renal impairment: The safety and effectiveness of lonafarnib have not been established in individuals with renal impairment, and caution should be exercised in this population.
Bleeding disorders: lonafarnib may cause a decrease in blood cell counts, which can enhance the risk of bleeding. Caution should be exercised in individuals with bleeding disorders, and blood counts should be monitored regularly.
Infections: lonafarnib may also increase the risk of infection due to decreased blood cell counts. Caution should be exercised in individuals with a history of infections, and signs of infection should be monitored closely.
Interactions with other medications: lonafarnib may interact with other medications, including CYP3A inhibitors and inducers, and caution should be maintained when using these drugs in combination.
QT prolongation: lonafarnib may cause QT prolongation, increasing the risk of potentially life-threatening cardiac arrhythmias. Caution should be exercised in individuals with a history of QT prolongation or other cardiac conditions.
Elderly: The safety and effectiveness of lonafarnib in elderly individuals have not been established, and caution should be exercised in this population.

Pregnancy consideration:

US FDA pregnancy category: Not assigned

Lactation:  

Excreted into human milk is Not known.

Pregnancy category:

Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.       
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women       
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.      
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.       
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.       
Category N: There is no data available for the drug under this category

Pharmacology:

Pharmacodynamics:

Mechanism of action: The method by which it works is through an FTI taken orally. The inhibitor targets Farnesyltransferase, an enzyme that modifies proteins through prenylation.

The accumulation of faulty lamin A protein renders the nucleus unstable, resulting in premature aging in children with progeria.

Pharmacokinetics:

Absorption

Distribution

lonafarnib is extensively distributed throughout the body, with a volume of distribution of approximately 0.5-1.5 L/kg. The drug is highly protein-bound, approximately 99% bound to plasma proteins.

Metabolism

Elimination and Excretion

lonafarnib and its metabolites are primarily eliminated in the feces, with only a tiny amount in the urine. The elimination half-life of lonafarnib is approximately 3-5 hours.

Administration:

Oral administration

lonafarnib is available as a capsule for oral administration. The capsules should be generally swallowed whole and not crushed or chewed.

Patient information leaflet

Generic Name: lonafarnib 

Pronounced: [ LOE-na-FAR-nib ]

Why do we use lonafarnib?

The specific uses of lonafarnib include:

Progeria: lonafarnib is approved for treating Hutchinson-Gilford Progeria Syndrome (HGPS), also known as progeria. This rare genetic disorder causes premature aging in children and is typically caused by a mutation in the LMNA gene. lonafarnib can improve weight gain, bone density, and cardiovascular function in individuals with HGPS.
Progeroid laminopathies: lonafarnib is also used to treat other progeroid laminopathies, which are rare genetic disorders similar to HGPS but have different genetic causes. These disorders include Mandibuloacral Dysplasia Type A (MADA), Mandibuloacral Dysplasia Type B (MADB), and Restrictive Dermopathy (RD).
Acute myeloid leukemia (AML): lonafarnib is currently being studied as a potential treatment for AML, a cancer affecting the blood and bone marrow. The drug acts by targeting a protein called RAS, which is often mutated in AML and can contribute to the growth, spread of cancer cells.

It is important to note that lonafarnib is only approved for use in specific indications and should only be used under the close monitor of a physician who is experienced in drug use.

Latest Posts

Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment

November 15, 2025

New Prediction Model Guides CKD Patients on Dialysis vs. Conservative Care

November 14, 2025

World’s TB Fight Faces Setback Amid Funding Gaps

November 13, 2025